Whole transcriptome analysis of multiple Sclerosis patients reveals active inflammatory profile in relapsing patients and downregulation of neurological repair pathways in secondary progressive cases

被引:10
|
作者
Nali, Luiz H. [1 ,2 ]
Olival, Guilherme S. [3 ]
Sousa, Francielle T. G. [1 ]
de Oliveira, Ana Carolina S. [1 ]
Montenegro, Horacio [4 ]
da Silva, Israel T. [5 ]
Dias-Neto, Emamnuel [5 ,6 ]
Naya, Hugo [7 ]
Spangenberg, Lucia [7 ]
Penalva-de-Oliveira, Augusto C. [8 ]
Romano, Camila M. [1 ,9 ]
机构
[1] Univ Sao Paulo, Lab Virol, Inst Medicina Trop Sao Paulo, LIM52 LIMHC, Rua Dr Eneas de Carvalho Aguiar, BR-05403000 Sao Paulo, Brazil
[2] Univ Santo Amaro, Postgraduat Program Hlth Sci, Rua Prof Eneas Siqueira Neto 340, BR-04829300 Sao Paulo, Brazil
[3] Dept Neurol Santa Casa Misericordia Sao Paulo, R Dr Cesario Mota Jr 112, BR-01221020 Sao Paulo, Brazil
[4] ESALQ USP, Dept Zootecnia, BR-13400183 Piracicaba, SP, Brazil
[5] AC Camargo Canc Ctr, Lab Med Genom, BR-01525001 Sao Paulo, Brazil
[6] Univ Sao Paulo, Sao Paulo Med Sch, Inst Psychiat, Lab Neurosci LIM 27, Sao Paulo, Brazil
[7] Unidad Bioinformat Inst Pasteur Montevideo, Mataojo 2020, Montevideo 11400, Uruguay
[8] Inst Infectol Emilio Ribas, Dept Neurol, Ave Doutor Arnaldo 165, BR-01246900 Sao Paulo, Brazil
[9] Univ Sao Paulo, Fac Med, Hosp Clin HCFMUSP LIM52, Sao Paulo, Brazil
基金
巴西圣保罗研究基金会;
关键词
Multiple Sclerosis; Transcriptome; gene expression; RRMS; SPMS; NERVE GROWTH-FACTOR; EXPERIMENTAL AUTOIMMUNE ENCEPHALOMYELITIS; GENE-EXPRESSION; PEPTIDYLARGININE DEIMINASE-2; INDUCTION; TYPE-1; PAD2; RISK; NATALIZUMAB; CYTOKINES;
D O I
10.1016/j.msard.2020.102243
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background: Multiple sclerosis (MS) is an inflammatory autoimmune neurologic disease that causes progressive destruction of myelin sheath and axons. Affecting more than 2 million people worldwide, MS may presents distinct clinical courses. However, information regarding key gene expression and genic pathways related to each clinical form is still limited. Objective: To assess the whole transcriptome of blood leukocytes from patients with remittent-recurrent (RRMS) and secondary-progressive (SPMS) forms to explore the gene expression profile of each form. Methods: Total RNA was obtained and sequenced in Illumina HiSeq platform. Reads were aligned to human genome (GRCh38/hg38), BAM files were mapped and differential expression was obtained with DeSeq2. Up or downregulated pathways were obtained through Ingenuity IPA. Pro-inflammatory cytokines levels were also assessed. Results: The transcriptome was generated for nine patients (6 SPMS and 3 RRMS) and 5 healthy controls. A total of 731 and 435 differentially expressed genes were identified in SPMS and RRMS, respectively. RERE, IRS2, SIPA1L1, TANC2 and PLAGL1 were upregulated in both forms, whereas PAD2 and PAD4 were upregulated in RRMS and downregulated in SPMS. Inflammatory and neuronal repair pathways were upregulated in RRMS, which was also observed in cytokine analysis. Conversely, SPMS patients presented IL-8, IL-1, Neurothrophin and Neuregulin pathways down regulated. Conclusions: Overall, the transcriptome of RRMS and SPMS clearly indicated distinct inflammatory profiles, where RRMS presented marked pro-inflammatory profile but SPMS did not. SPMS individuals also presented a decrease on expression of neuronal repair pathways.
引用
收藏
页数:9
相关论文
共 50 条
  • [31] Safety of ocrelizumab in multiple sclerosis: Up to 11 years of updated analysis in patients with relapsing and progressive multiple sclerosis
    Hauser, Stephen
    Kappos, Ludwig
    Montalban, Xavier
    Chognot, Cathy
    Pasquarelli, Noemi
    Singh, Varinder
    Incera, Elodie
    Wolinsky, Jerry
    MULTIPLE SCLEROSIS JOURNAL, 2024, 30 (03) : 333 - 334
  • [32] Escalating immunotherapy with mitoxantrone in patients with very active relapsing-remitting or progressive multiple sclerosis
    Cursiefen, S
    Flachenecker, P
    Toyka, KV
    Rieckmann, P
    EUROPEAN NEUROLOGY, 2000, 43 (03) : 186 - 187
  • [33] Efficacy of Siponimod in secondary progressive multiple sclerosis patients with active disease: the EXPAND study subgroup analysis
    Gold, R.
    Kappos, L.
    Bar-Or, A.
    Vermersch, P.
    Giovannoni, G.
    Fox, R.
    Rouyrre, N.
    Karlsson, G.
    Cree, B. A. C.
    MULTIPLE SCLEROSIS JOURNAL, 2019, 25 : 380 - 381
  • [34] Differential oxidative stress and cytokine profile between progressive and relapsing-remitting multiple sclerosis patients
    Kallaur, A. P.
    Oliveira, S. R.
    Schiavao, L. J. V.
    Rodrigues, P. R. V. P.
    Alfieri, D. F.
    Pereira, W. L. C. J.
    Delongui, F.
    Rodrigues, D. F.
    Lopes, J.
    Morimoto, H. K.
    Kaimen-Maciel, D. R.
    Simao, A. N. C.
    Reiche, E. M. V.
    MULTIPLE SCLEROSIS JOURNAL, 2014, 20 : 370 - 370
  • [35] Neurotrophic factors in relapsing remitting and secondary progressive multiple sclerosis patients during interferon beta therapy
    Caggiula, M
    Batocchi, AP
    Frisullo, G
    Angelucci, F
    Patanella, AK
    Sancricca, C
    Nociti, V
    Tonali, PA
    Mirabella, M
    CLINICAL IMMUNOLOGY, 2006, 118 (01) : 77 - 82
  • [36] Apoptosis of cerebrospinal fluid lymphocytes in patients with relapsing-remitting, primary and secondary progressive multiple sclerosis
    Petelin, Z
    Brinar, V
    Zurak, N
    Dubravcic, K
    Botinic, D
    Ivankovic, D
    MULTIPLE SCLEROSIS JOURNAL, 2005, 11 : S125 - S126
  • [37] The experience of transitioning from relapsing remitting to secondary progressive multiple sclerosis: views of patients and health professionals
    O'Loughlin, Emer
    Hourihan, Susan
    Chataway, Jeremy
    Playford, E. Diane
    Riazi, Afsane
    DISABILITY AND REHABILITATION, 2017, 39 (18) : 1821 - 1828
  • [38] Fatigue predicts conversion to secondary progressive disease phenotype in relapsing-remitting multiple sclerosis patients
    Cavallari, M.
    Palotai, M.
    Prieto, J. C.
    Healy, B. C.
    Egorova, S.
    Polgar-Turcsanyi, M.
    Anderson, M.
    Glanz, B.
    Chitnis, T.
    Guttmann, C. R. G.
    MULTIPLE SCLEROSIS JOURNAL, 2015, 21 : 465 - 466
  • [39] Cost-utility of interferon β1b in the treatment of patients with active relapsing-remitting or secondary progressive multiple sclerosis
    G. Kobelt
    L. Jönsson
    S. Fredrikson
    The European Journal of Health Economics, 2003, 4 (1) : 50 - 59
  • [40] Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis
    Lizak, Nathaniel
    Malpas, Charles B.
    Sharmin, Sifat
    Havrdova, Eva Kubala
    Horakova, Dana
    Izquierdo, Guillermo
    Eichau, Sara
    Lugaresi, Alessandra
    Duquette, Pierre
    Girard, Marc
    Prat, Alexandre
    Larochelle, Catherine
    Trojano, Maria
    Grand'Maison, Francois
    Grammond, Pierre
    Sola, Patrizia
    Ferraro, Diana
    Hupperts, Raymond
    Bergamaschi, Roberto
    Boz, Cavit
    Van Pesch, Vincent
    Spitaleri, Daniele
    Terzi, Murat
    Kalincik, Tomas
    JAMA NEUROLOGY, 2020, 77 (11) : 1398 - 1407